Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,netBorrowings,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,exchange,marketState,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,priceHint,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Apr 14, 2021) 4","Short Ratio (Apr 14, 2021) 4","Short % of Float (Apr 14, 2021) 4","Short % of Shares Outstanding (Apr 14, 2021) 4","Shares Short (prior month Mar 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,KALV,58565000,24308200,,,-10048000,,-10048000,3560000,-9097000,-12657000,-12657000,,,,,,0,0,12657000,9097000,2609000,,-10048000,-10048000,212694000,7641000,58565000,66206000,18000,-152880000,-1267000,181000,17727000,6518000,-1267000,3521000,62504000,32584000,7589000,641000,6959000.0,-1628000.0,6945000.0,1703000.0,2943000.0,1703000.0,1553000.0,491000.0,-7586000.0,136000.0,1010000.0,-14000.0,,55986000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,20.76,1630526402,0.3199997,20.5,20.87,20.11,90800,"KalVista Pharmaceuticals, Inc.",NGM,PRE,-0.20068188,0,False,False,1.5655563,20.11 - 20.87,20.44,0.0,0.0,8,14,finmb_136678928,NasdaqGM,"KalVista Pharmaceuticals, Inc.",USD,204854,123385,8.75,0.7285595,12.01 - 45.0,-24.24,-0.53866667,12.01,45.0,1479772800,1615444200,1631536200,1631881800,-2.117,-2.71,2,-3.19,-6.507837,3.25,20.236286,0.52371407,0.02587995,25.972137,-5.212137,504638240,-7.6605167,6.3876925,15,America/New_York,EDT,-14400000,2.07,,,45.0,12.01,20.24,25.97,204.85k,123.39k,24.31M,,21.28M,6.57%,68.90%,1.3M,3,6.44%,5.35%,777.39k,,,,,,0.00%,"Nov 21, 2016",,1:14,"Nov 21, 2016","Apr 29, 2020","Jan 30, 2021",0.00%,"-1,277.14%",-36.09%,-51.07%,3.82M,0.21,,-27.5M,-48.31M,-37.87M,-2.12,,50.31M,2.07,1.72M,2.93,9.59,3.25,-31.74M,-22.29M,Value,02142,Healthcare,56,9,3,"KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.",Cambridge,857 999 0075,MA,8,1609372800,1619740800,9,United States,http://www.kalvista.com,86400,9,55 Cambridge Parkway,866 553 3269,Biotechnology,Suite 901 East
t-1,KALV,64980000,24308200,,,-10426000,,-10426000,3633000,-9148000,-12781000,-12781000,,,,,,0,0,12781000,9148000,2355000,,-10426000,-10426000,209750000,10468000,64980000,75448000,18000,-142832000,-1956000,178000,16174000,9536000,-1956000,3194000,72076000,39700000,14685000,2173000,6384000.0,411000.0,6371000.0,60000.0,387000.0,60000.0,-1840000.0,-319000.0,-7952000.0,133000.0,1544000.0,-13000.0,,62540000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,20.76,1630526402,0.3199997,20.5,20.87,20.11,90800,"KalVista Pharmaceuticals, Inc.",NGM,PRE,-0.20068188,0,False,False,1.5655563,20.11 - 20.87,20.44,0.0,0.0,8,14,finmb_136678928,NasdaqGM,"KalVista Pharmaceuticals, Inc.",USD,204854,123385,8.75,0.7285595,12.01 - 45.0,-24.24,-0.53866667,12.01,45.0,1479772800,1615444200,1631536200,1631881800,-2.117,-2.71,2,-3.19,-6.507837,3.25,20.236286,0.52371407,0.02587995,25.972137,-5.212137,504638240,-7.6605167,6.3876925,15,America/New_York,EDT,-14400000,2.07,,,45.0,12.01,20.24,25.97,204.85k,123.39k,24.31M,,21.28M,6.57%,68.90%,1.3M,3,6.44%,5.35%,777.39k,,,,,,0.00%,"Nov 21, 2016",,1:14,"Nov 21, 2016","Apr 29, 2020","Jan 30, 2021",0.00%,"-1,277.14%",-36.09%,-51.07%,3.82M,0.21,,-27.5M,-48.31M,-37.87M,-2.12,,50.31M,2.07,1.72M,2.93,9.59,3.25,-31.74M,-22.29M,Value,02142,Healthcare,56,9,3,"KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.",Cambridge,857 999 0075,MA,8,1609372800,1619740800,9,United States,http://www.kalvista.com,86400,9,55 Cambridge Parkway,866 553 3269,Biotechnology,Suite 901 East
t-2,KALV,74435000,24308200,,,-10814000,,-10814000,3278000,-11165000,-14443000,-14443000,,,,,,0,0,14443000,11165000,3629000,,-10814000,-10814000,208442000,9467000,74435000,83902000,18000,-132406000,-1619000,178000,18014000,8457000,-1619000,3499000,80225000,46317000,12638000,1774000,5535000.0,35000.0,5513000.0,46000.0,6301000.0,46000.0,2225000.0,254000.0,-3588000.0,128000.0,762000.0,-22000.0,,71768000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,20.76,1630526402,0.3199997,20.5,20.87,20.11,90800,"KalVista Pharmaceuticals, Inc.",NGM,PRE,-0.20068188,0,False,False,1.5655563,20.11 - 20.87,20.44,0.0,0.0,8,14,finmb_136678928,NasdaqGM,"KalVista Pharmaceuticals, Inc.",USD,204854,123385,8.75,0.7285595,12.01 - 45.0,-24.24,-0.53866667,12.01,45.0,1479772800,1615444200,1631536200,1631881800,-2.117,-2.71,2,-3.19,-6.507837,3.25,20.236286,0.52371407,0.02587995,25.972137,-5.212137,504638240,-7.6605167,6.3876925,15,America/New_York,EDT,-14400000,2.07,,,45.0,12.01,20.24,25.97,204.85k,123.39k,24.31M,,21.28M,6.57%,68.90%,1.3M,3,6.44%,5.35%,777.39k,,,,,,0.00%,"Nov 21, 2016",,1:14,"Nov 21, 2016","Apr 29, 2020","Jan 30, 2021",0.00%,"-1,277.14%",-36.09%,-51.07%,3.82M,0.21,,-27.5M,-48.31M,-37.87M,-2.12,,50.31M,2.07,1.72M,2.93,9.59,3.25,-31.74M,-22.29M,Value,02142,Healthcare,56,9,3,"KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.",Cambridge,857 999 0075,MA,8,1609372800,1619740800,9,United States,http://www.kalvista.com,86400,9,55 Cambridge Parkway,866 553 3269,Biotechnology,Suite 901 East
t-3,KALV,83752000,24308200,,,-6708000,,-6584000,3296000,-5661000,-8957000,-8957000,,,,,,-124000,3824000,12781000,9485000,2249000,,-6584000,-6584000,207208000,8777000,83752000,92529000,18000,-121592000,-1882000,178000,15789000,7720000,-1882000,3655000,88696000,51925000,16527000,1677000,10035000.0,-4961000.0,10027000.0,1000.0,-2172000.0,2000.0,-2826000.0,-236000.0,-12618000.0,-288000.0,1387000.0,-8000.0,-1000.0,80976000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,20.76,1630526402,0.3199997,20.5,20.87,20.11,90800,"KalVista Pharmaceuticals, Inc.",NGM,PRE,-0.20068188,0,False,False,1.5655563,20.11 - 20.87,20.44,0.0,0.0,8,14,finmb_136678928,NasdaqGM,"KalVista Pharmaceuticals, Inc.",USD,204854,123385,8.75,0.7285595,12.01 - 45.0,-24.24,-0.53866667,12.01,45.0,1479772800,1615444200,1631536200,1631881800,-2.117,-2.71,2,-3.19,-6.507837,3.25,20.236286,0.52371407,0.02587995,25.972137,-5.212137,504638240,-7.6605167,6.3876925,15,America/New_York,EDT,-14400000,2.07,,,45.0,12.01,20.24,25.97,204.85k,123.39k,24.31M,,21.28M,6.57%,68.90%,1.3M,3,6.44%,5.35%,777.39k,,,,,,0.00%,"Nov 21, 2016",,1:14,"Nov 21, 2016","Apr 29, 2020","Jan 30, 2021",0.00%,"-1,277.14%",-36.09%,-51.07%,3.82M,0.21,,-27.5M,-48.31M,-37.87M,-2.12,,50.31M,2.07,1.72M,2.93,9.59,3.25,-31.74M,-22.29M,Value,02142,Healthcare,56,9,3,"KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.",Cambridge,857 999 0075,MA,8,1609372800,1619740800,9,United States,http://www.kalvista.com,86400,9,55 Cambridge Parkway,866 553 3269,Biotechnology,Suite 901 East
